Abstract
Interleukin-1β (IL-1β) is a pleiotropic cytokine that exerts multiple roles in both physiological and pathological conditions. It is produced by different cell subsets, and drives a wide range of inflammatory responses in numerous target cells. Enhanced IL-1β signaling is a common event in patients of hematological malignancies. Recent body of evidence obtained in preclinical models shows the pathogenic role of these alterations, and the promising therapeutic value of IL-1 targeting. In this review, we further highlight a potential contribution of IL-1β linking to complications and autoimmune disease that should be investigated in future studies. Hence, drugs that target IL-1 may be helpful to improve outcome or reduce morbidity in patients. Some of them are FDA-approved, and used efficiently against autoimmune diseases, like IL-1 receptor antagonist. In the clinic, however, this agent seems to have limited properties. Current improved drugs will allow to determine the true potential of IL-1 and IL-1β targeting as therapy in hematological malignancies and their related complications.
Citations
Mar 3, 2018·Neurochemical Research·Xu ChuQingxia Kong
Nov 29, 2017·Frontiers in Oncology·Shayda HemmatiKira Gritsman
Aug 31, 2018·International Journal of Molecular Sciences·Joanna Konieczny, Lorena Arranz
Jan 13, 2019·Blood·Iris Z UrasVeronika Sexl
Jun 22, 2019·Poultry Science·Zhi-Yong XuJin-You Ma
May 1, 2020·EMBO Reports·Ao ZhangMu-Sheng Zeng
May 31, 2020·International Journal of Molecular Sciences·Giuliana AsconeTeun J de Vries
Sep 2, 2020·Hematological Oncology·Tianxin LyuYongping Song
Aug 10, 2019·International Journal of Molecular Sciences·Anne Sophie Kubasch, Uwe Platzbecker
Sep 7, 2018·Frontiers in Immunology·Wei-Ting WongKuo-Feng Hua
May 31, 2019·Cancer Medicine·Yujiao WuJihui Jia
Nov 30, 2019·International Journal of Molecular Sciences·Muamera SarajlicJutta Horejs-Hoeck
Jan 5, 2020·International Journal of Oral Science·Ran ChengTao Hu
May 24, 2020·Journal of Clinical Medicine·Alice PievaniMarta Serafini
Sep 3, 2020·Cancers·Sophie Allain-MailletSylvie Hermouet
Jul 17, 2019·European Journal of Medicinal Chemistry·Ahmed H E HassanYong Sup Lee
Dec 11, 2020·The British Journal of Nutrition·Qianqian XuXinyang Dong
Nov 25, 2020·Biomedicines·Oana MesarosMihnea Zdrenghea
Feb 3, 2021·International Journal of Molecular Sciences·Laura UrwanischJutta Horejs-Hoeck
Mar 11, 2021·Science Signaling·Hema KothariColeen A McNamara
May 12, 2021·Scientific Reports·Fabíola Silva AlvesAllyson Guimarães Costa
Jun 16, 2021·Scientific Reports·Parastoo ModarresSadeq Vallian
Nov 3, 2021·Environmental Toxicology·Subhashree Bhattacharyya, Sujata Law
Dec 3, 2021·Leukemia & Lymphoma·Julian A WaksalJohn O Mascarenhas